Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors are now widely used in the treatment of patients with type 2 diabetes, chronic kidney disease and heart failure.121, 122, 123. Here, SLC5A2 is linked to type 2 diabetes mellitus.